Table II.

Consequences in 23 children with haematological malignancies (5 IgM +ve, 18 IgM -ve)

S. No.	Clinical condition	Status of B19 IgM antibodies
1.	Prolonged unexplained anaemia	4 of 5 (80%) of IgM +ve group vs 4 of 18 (22 %) of IgM -ve group (P<0.033)
2.	Blood transfusion requirements	6.6 ± 4.8 Units in IgM +ve group vs 3.0 ± 2.6 Units in IgM -ve group (P<0.036)
3.	Delay in induction chemotherapy (> 7 days)	3 of 5 (60%) B19 IgM +ve group vs 5 of 18 (27.7 %) B19 IgM -ve group (P<0.18)
4.	Duration of delay in chemotherapy	29.2 ± 20 days in IgM +ve vs 6.3 ± 7.8 days in B19 IgM -ve (P<0.02)